Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy

Cancer

Volumn 118, Issue 20, 2012, Pages 4944-4952

  Ho, Alice Y ^a   Gupta, Gaorav ^a   King, Tari A ^a   Perez, Carmen A ^a   Patil, Sujata M ^a   Rogers, Katherine H ^a   Wen, Yong Hannah ^a   Brogi, Edi ^a   Morrow, Monica ^a   Hudis, Clifford A ^a   Traina, Tiffany ^a   McCormick, Beryl ^a   Powell, Simon N ^a   Robson, Mark E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

breast cancer; breast conserving therapy; outcomes; prognosis; T1a; T1b; T1N0; triple negative

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; GENE MUTATION; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 84867330656     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27480     Document Type: Article

References (19)

1. Fracheboud J, de Koning HJ, Beemsterboer PM, et al. Nation-wide breast cancer screening in the Netherlands: results of initial and subsequent screening 1990-1995. National Evaluation Team for Breast Cancer Screening. Int J Cancer. 1998; 75: 694-698.
2. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13 (15 pt 1): 4429-4434.
4. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.
5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26: 1275-1281.
6. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26: 2373-2378.
7. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007; 25: 4952-4960.
8. Albert JM, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 1296-1302.
9. Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less [serial online]. BMC Cancer. 2010; 10: 557.
10. Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011; 127: 713-720.
11. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V,. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109: 1721-1728.
12. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
13. North Center Cancer Network (NCCN). NCCN Clinical Practical Guidelines in Oncology Breast Cancer Guidelines. Version 2.2009. Fort Washington, PA: NCCN; 2009. Available from: http://www.nccn.org. Accessed May 11, 2011.
14. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ,. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer. 2009. Ann Oncol. 2009; 20: 1319-1329.
15. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S,. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011; 29: 2852-2858.
16. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1108-1112.
17. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008; 111: 405-410.
18. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795.
19. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA,. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009; 115: 423-428.